𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease

✍ Scribed by Anna Prats París; Heidi Guerra Saleta; Maria de la Cruz Crespo Maraver; Emmanuel Silvestre; Maite Garolera Freixa; Cristina Petit Torrellas; Silvia Alonso Pont; Marc Fabra Nadal; Sheila Alcaine Garcia; Maria Victoria Perea Bartolomé; Valentina Ladera Fernández; Àngels Rusiñol Bayés

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
293 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The aim of this study was to analyze the efficacy of a cognitive training program on cognitive performance and quality of life in nondemented Parkinson's disease patients. Participants who met UK Brain Bank diagnosis criteria for Parkinson's disease, with I–III Hoehn & Yahr, aged 50–80, and nondemented (Mini‐Mental State Examination ≥ 23) were recruited. Patient's cognitive performance and functional and quality‐of‐life measures were assessed with standardized neuropsychological tests and scales at baseline and after 4 weeks. Subjects were randomly and blindly allocated by age and premorbid intelligence (Vocabulary, Wechsler Adult Intelligence Scale‐III) into 2 groups: an experimental group and a control group. The experimental group received 4 weeks of 3 weekly 45‐minute sessions using multimedia software and paper‐and‐pencil cognitive exercises, and the control group received speech therapy. A total of 28 patients were analyzed. Compared with the control group participants (n = 12), the experimental group participants (n = 16) demonstrated improved performance in tests of attention, information processing speed, memory, visuospatial and visuoconstructive abilities, semantic verbal fluency, and executive functions. There were no observable benefits in self‐reported quality of life or cognitive difficulties in activities of daily living. We concluded that intensive cognitive training may be a useful tool in the management of cognitive functions in Parkinson's disease. © 2011 Movement Disorder Society

📜 SIMILAR VOLUMES

Clinical efficacy of istradefylline (KW-
Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study
✍ Yoshikuni Mizuno; Kazuko Hasegawa; Tomoyoshi Kondo; Sadako Kuno; Mitsutoshi Yama 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 1 views

## Abstract The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose of 20 mg or 40 mg once daily for 12 weeks in Parkinson's disease (PD) patients with motor complications on levodopa therapy based on the change in the daily OFF time compared with placebo and to

Safety and efficacy of perampanel in adv
Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study
✍ Karla Eggert; David Squillacote; Paolo Barone; Richard Dodel; Regina Katzenschla 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

Squillacote, received compensation from Eisai for their site's conduct of the study. Drs. Barone, Lees, and Oertel received honoraria from Eisai as members of the Advisory Board of this study. Dr. Rascol has received unrestricted scientific grant and honoraria from Eisai for his advice to the compan

Randomized placebo-controlled trial of d
Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease
✍ Iracema Leroi; Jason Brandt; Stephen G. Reich; Constantine G. Lyketsos; Stephen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

## Abstract ## Objective To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD). ## Methods Using a randomized, double‐blind, placebo‐controlled design, nine patients rec

The effects of rasagiline on cognitive d
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study
✍ Hasmet A. Hanagasi; Hakan Gurvit; Pınar Unsalan; Hilal Horozoglu; Nese Tuncer; A 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

## Abstract Cognitive impairment can occur at all stages of Parkinson's disease. Rasagiline is a selective monoamine oxidase type‐B inhibitor that enhances central dopaminergic transmission. Dopamine is thought to be involved in certain cognitive processes such as working memory. We assessed the ef

Controlled study of decision-making and
Controlled study of decision-making and cognitive impairment in Parkinson's disease
✍ Javier Pagonabarraga; Carmen García-Sánchez; Gisela Llebaria; Berta Pascual-Seda 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract Impulse control disorders (ICD) related to reward‐processing dysfunction have been reported in Parkinson's disease (PD). The relationship between clinical markers of limbic dysfunction with demographic variables and cognitive status of PD is incompletely known. Our objective was to furt

Double-blind, randomized, controlled tri
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
✍ Matthew B. Stern; Kenneth L. Marek; Joseph Friedman; Robert A. Hauser; Peter A. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 2 views

## Abstract Rasagiline (__N__‐propargyl‐1(__R__)‐aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase‐B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients n